newsfilter
← Latest News
GlobeNewswire·

Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Company continues to advance ALRN-6924 as a selective chemoprotective agent for all patients with p53-mutated cancer, with immediate focus on breast cancer clinical trial Extended cash runway expected to support operations through end of 1Q 2024 Prese